Phosphodiesterase 3A expression is modulated by nitric oxide in rat pulmonary artery smooth muscle cells

Journal of Physiology and Pharmacology

Volumn 61, Issue 6, 2010, Pages 663-669

  Busch, C J ^a,b   Graveline, A R ^a   Jiramongkolchai, K ^a   Liu, H ^a   Sanchez, L S ^a   Bloch, K D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cyclic guanosine monophosphate; GSNO; Nitric oxide; Phosphodiesterase 3A; Soluble guanylate cyclase; Vasodilation

Indexed keywords

DACTINOMYCIN; GUANYLATE CYCLASE; INTERLEUKIN 1BETA; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IIIA; RNA POLYMERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HYDROLYSIS; IMMUNOREACTIVITY; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN SYNTHESIS; PULMONARY ARTERY; RAT; SMOOTH MUSCLE FIBER;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; CELLS, CULTURED; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GUANYLATE CYCLASE; INTERLEUKIN-1BETA; LYSINE; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; NITRIC OXIDE DONORS; OXADIAZOLES; PULMONARY ARTERY; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; S-NITROSOGLUTATHIONE; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 79251502975     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002; 53: 503-514.
2. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003; 93: 280-291.
3. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100: 309-327.
4. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994; 266: L536-L543.
5. Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, Giembycz MA Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 2003; 284: L279-L289.
6. D'Andrea MR, Qiu Y, Haynes-Johnson D, Bhattacharjee S, Kraft P, Lundeen S. Expression of PDE11A in normal and malignant human tissues. J Histochem Cytochem 2005; 53: 895-903.
7. Phillips PG, Long L, Wilkins MR, Morrell NW. cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 2005; 288: L103-L115.
8. Evgenov OV, Busch CJ, Evgenov NV, et al. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 290: L723-L729.
9. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-398.
10. Matsumoto T, Kobayashi T Kamata K. Phosphodiesterases in the vascular system. J Smooth Muscle Res 2003; 39: 67-86.
11. Maclean MR, Johnston ED, Mcculloch KM, Pooley L, Houslay MD, Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997; 283: 619-624.
12. Pauvert O, Salvail D, Rousseau E, Lugnier C, Marthan R, Savineau JP. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 2002; 63: 1763- 1772.
13. Beltman J, Becker DE, Butt E, et al. Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains. Mol Pharmacol 1995; 47: 330-339.
14. Movsesian MA. PDE3 cyclic nucleotide phosphodiesterases and the compartmentation of cyclic nucleotide-mediated signalling in cardiac myocytes. Basic Res Cardiol 2002; 97(S1): 83-90.
15. Hambleton R, Krall J, Tikishvili E, et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 2005; 280: 39168-39174.
16. Choi YH, Ekholm D, Krall J, et al. Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J 2001; 353: 41-50.
17. Liu H and Maurice DH. Expression of cyclic GMP- inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 1998; 125: 1501-1510.
18. Tarpey SB, Sawmiller DR, Kelly C, Thompson WJ, Townsley MI. Phosphodiesterase 3 activity is reduced in dog lung following pacing-induced heart failure. Am J Physiol Lung Cell Mol Physiol 2003; 284: L766-L773.
19. Hung SH, Zhang W, Pixley RA, et al. New insights from the structure-function analysis of the catalytic region of human platelet phosphodiesterase 3A: a role for the unique 44- amino acid insert. J Biol Chem 2006; 281: 29236-29244.
20. Takata M, Filippov G, Liu H, et al. Cytokines decrease sGC in pulmonary artery smooth muscle cells via NO-dependent and NO-independent mechanisms. Am J Physiol Lung Cell Mol Physiol 2001; 280: L272-L278.
21. Busch CJ, Liu H, Graveline AR, Bloch KD. Nitric oxide induces phosphodiesterase 4B expression in rat pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2006; 290: L747-L753.
22. Murray F, Maclean MR, Pyne NJ. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002; 137: 1187-1194.
23. Liu H, Palmer D, Jimmo SL, et al. Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells. J Biol Chem 2000; 275: 26615-26624.
24. Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, Movsesian MA. Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 2002; 277: 38072-38078.
25. Aizawa T, Wei H, Miano JM, Abe J, Berk BC, Yan C. Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 2003; 93: 406-413.
26. Sausbier M, Schubert R, Voigt V, et al. Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res 2000; 87: 825-830.
27. Fischmeister R, Castro LR, Abi-Gerges A, et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 2006; 99: 816-828.
28. Worner R, Lukowski R, Hofmann F, Wegener JW. cGMP signals mainly through cAMP kinase in permeabilized murine aorta. Am J Physiol Heart Circ Physiol 2007; 292: H237-H244.
29. Yan C, Miller CL, Abe J. Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 2007; 100: 489-501.
30. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005; 97: 618-628.
31. Black SM, Heidersbach RS, McMullan DM, Bekker M, Johengen MJ, Fineman JR. Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension. Am J Physiol 1999; 277: H1849-H1856.
32. Ross GA, Oishi P, Azakie A, et al. Endothelial alterations during inhaled NO in lambs with pulmonary hypertension: implications for rebound hypertension. Am J Physiol Lung Cell Mol Physiol 2005; 288: L27-L35.
33. Ivy DD, Kinsella JP, Ziegler JW, Abman SH. Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease. J Thorac Cardiovasc Surg 1998; 115: 875-882.
34. Thelitz S, Oishi P, Sanchez LS. Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs. Pediatr Crit Care Med 2004; 5: 234-239.
35. Mokry J, Mokra D, Nosalova G, Beharkova M, Feherova Z. Influence of selective inhibitors of phosphodiesterase 3 and 4 on cough and airway reactivity. J Physiol Pharmacol 2008; 59(Suppl 6): 473-482.
36. Nejman-Gryz P, Grubek-Jaworska H, Glapinski J, Hoser G, Chazan R. Effects of the phosphodiestrase-4 inhibitor rolipram on lung resistance and inflammatory reaction in experimental asthma. J Physiol Pharmacol 2006; 57(Suppl 4): 29-239.
37. Schermuly RT, Yilmaz H, Ghofrani HA, et al. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 2005; 172: 358-363.
38. Filippov G, Bloch DB, Bloch KD. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest 1997; 100: 942-948.
39. Axelsson KL, Andersson RG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 1983; 88: 71-79.
40. Schroder H, Leitman DC, Bennett BM, Waldman SA, Murad F. Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts, J Pharmacol Exp Ther 1988; 245: 413-418.